ESLAW icon

Estrella Immunopharma, Inc. Warrant

0.0360 USD
0.0000
0%
At close Updated Aug 28, 4:00 PM EDT
1 day
0%
5 days
-37.17%
1 month
11.46%
3 months
0.84%
6 months
-40%
Year to date
-60.48%
1 year
-64%
5 years
-90%
10 years
-90%
 

About: Estrella Immunopharma Inc is a clinical-stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS T-cell therapies with the capacity to address treatment challenges for patients with blood cancers and solid tumors. Estrella's mission is to harness the evolutionary power of the human immune system to transform the lives of patients fighting cancer and autoimmune diseases.

0
Funds holding %
of 7,444 funds
Analysts bullish %

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

20% more funds holding

Funds holding: 10 [Q1] → 12 (+2) [Q2]

0.11% more ownership

Funds ownership: 2.02% [Q1] → 2.13% (+0.11%) [Q2]

0% more repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 1

20% less capital invested

Capital invested by funds: $262K [Q1] → $208K (-$53.7K) [Q2]

Financial journalist opinion

We haven’t received any recent news articles for ESLAW

Charts implemented using Lightweight Charts™